SCA
GNCA

SAC Capital Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

SAC Capital Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,468
Closed -$359K – 1295
2014
Q1 		$359K Buy
+2,468
New +$302K ﹤0.01% 1326

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SAC Capital Advisors's GNCA Position: Q2 2014 in Review

SAC Capital Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2014, closing a stake of 2,468 shares — an estimated $359K sold.

SAC Capital Advisors first reported a position in GNCA in Q1 2014 and held it in 1 quarter. The position peaked at $359K in Q1 2014. 41 funds tracked by Wall St. Rank hold GNCA as of Q2 2014.

  • SAC Capital Advisors reported no remaining Genocea Biosciences, Inc. position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 2,468 Genocea Biosciences, Inc. shares in Q2 2014, an estimated $359K.
  • SAC Capital Advisors first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Genocea Biosciences, Inc. position peaked at $359K in Q1 2014.
  • 41 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.